Expertise in
7
conditions

Adrian C. Bloor

Wimslow Road, 
Manchester, ENG, GB 
Expertise in
7
conditions
Wimslow Road, 
Manchester, ENG, GB 

Overview

Adrian Bloor practices practicing medicine in Manchester, United Kingdom.

Mr. Bloor is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Wimslow Road, Manchester, ENG, United Kingdom
Other Locations
550 Wilmslow Road, Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers
Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers
Enrollment Status: Unknown
Publish Date: February 12, 2019
Intervention Type: Other
Study Drug: CD4 Donor Lymphocytes
Study Phase: Phase 2
View 4 Less Clinical Trials

74 Total Publications

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.
Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: June 16, 2026

Frequently Asked Questions about Adrian C. Bloor

Is Adrian C. Bloor a top-rated expert for Small Lymphocytic Lymphoma (SLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Adrian C. Bloor is classified as an Advanced expert for Small Lymphocytic Lymphoma (SLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Adrian C. Bloor participate in research or clinical trials?

Yes. Adrian C. Bloor has published 74 articles and abstracts on conditions like Small Lymphocytic Lymphoma (SLL). You can view a list of Adrian C. Bloor's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bloor's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile